CORC

在结果中检索

CORC

浏览/检索结果: 共43条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Mechanical responses and crystal plasticity model of CoCrNi medium-entropy alloy under ramp wave compression 期刊论文
MATTER AND RADIATION AT EXTREMES, 2024, 卷号: 9, 期号: 5, 页码: 16
作者:  Dong, Jinlei;  Zhang, Xuping;  Wang, Guiji;  Wu, Xianqian;  Luo, Binqiang
收藏  |  浏览/下载：0/0  |  提交时间：2024/07/26
Friction and wear behavior of bioinspired composites with nacre-like lamellar and brick-and-mortar architectures against human enamel 期刊论文
JOURNAL OF MATERIALS SCIENCE & TECHNOLOGY, 2022, 卷号: 128, 页码: 133-141
作者:  Gao, Kefeng;  Guan, Jianjun;  Sun, Hui;  Han, Chengwei;  Tan, Guoqi
收藏  |  浏览/下载：37/0  |  提交时间：2022/07/14
A novel pancreatic cancer model originated from transformation of acinar cells in adult tree shrew, a primate-like animal 期刊论文
DISEASE MODELS & MECHANISMS, 2019, 卷号: 12, 期号: 4
作者:  Tu, Qiu;  Yang, Dong;  Zhang, Xianning;  Jia, Xintong;  An, Sanqi
收藏  |  浏览/下载：38/0  |  提交时间：2019/12/04
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：61/0  |  提交时间：2019/12/05
Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results 期刊论文
HEPATOLOGY INTERNATIONAL, 2019, 卷号: 13, 期号: 3
作者:  Liang, Xieer;  Gao, Zhiliang;  Xie, Qing;  Zhang, Jiming;  Sheng, Jifang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：48/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：39/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：40/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：33/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：31/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace